Does IL-6 drive B cells to become antibody-secreting plasma cells and amplify humoral responses during chronic antigen exposure?

Interleukin-6 (IL-6) is a pleiotropic cytokine that serves as a fundamental regulator of the humoral immune response. Originally identified as B-cell stimulatory factor 2 (BSF-2), its primary physiological role is to bridge the gap between innate signaling and the production of specific antibodies.

Mechanistic basis of plasma cell differentiation

The transition of a B cell into a specialized antibody-secreting plasma cell is driven by a precise molecular program initiated by IL-6.

• STAT3-Blimp-1 Axis: IL-6 binds to the IL-6R/gp130 receptor complex, activating the JAK/STAT3 signaling pathway. Phosphorylated STAT3 acts as a master transcriptional regulator that directly induces the expression of Blimp-1 (encoded by Prdm1).
• Lineage Commitment: Blimp-1 functions as a transcriptional repressor of B-cell identity genes (such as Pax5 and Bcl6) while simultaneously activating the plasma cell program.
• Secretory Machinery: Following Blimp-1 induction, the upregulation of XBP1 expands the endoplasmic reticulum, providing the cellular infrastructure necessary for the high-rate secretion of immunoglobulins.

Amplification during chronic antigen exposure

In contexts of chronic antigen exposure, such as persistent viral infections or autoimmune disorders, IL-6 acts as a critical amplifier of the humoral arm.

• Sustaining Germinal Centers: Chronic exposure to antigens (e.g., EBV or self-antigens) triggers continuous IL-6 production from monocytes and stromal cells. This supports the survival and differentiation of T follicular helper (Tfh) cells, which are essential for maintaining germinal center (GC) reactions and B-cell maturation.
• Hypergammaglobulinemia: Clinical models demonstrate that IL-6 overexpression leads to polyclonal antibody overproduction (hypergammaglobulinemia). This is observed in conditions like Castleman's disease and multiple myeloma, where IL-6 sustains the survival and proliferation of secreting cells.
• Clinical Implications: While acute scenarios like SARS-CoV-2 show complex interactions where IL-6 blockade can sometimes increase peak titers—likely due to delayed viral clearance extending the antigenic stimulus—the core evidence confirms that IL-6 is required for the sustained output of antibodies during prolonged immune challenges.

Bottom line

Interleukin-6 is a critical driver of the B-cell to plasma cell transition through the STAT3-Blimp-1-XBP1 molecular axis. During chronic antigen exposure, it amplifies humoral immunity by sustaining T-follicular helper cell activity and germinal center responses, ultimately leading to enhanced antibody secretion.